Premium
Long‐term inhibitory effects of a novel anti‐estrogen on the growth of ZR‐75‐1 and MCF‐7 human breast cancer tumors in nude mice
Author(s) -
Luo Shouqi,
Martel Céline,
Gauthier Sylvain,
Mérand Yves,
Bélanger Alain,
Labrie Claude,
Labrie Fernand
Publication year - 1997
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19971127)73:5<735::aid-ijc21>3.0.co;2-3
Subject(s) - estrogen , medicine , endocrinology , mcf 7 , uterus , nude mouse , estrogen receptor , breast cancer , endogeny , mammary gland , ovary , cancer , biology , human breast
The effects of the novel anti‐estrogen EM‐343 on the growth of 2 hormone‐responsive human breast cancer tumors have been examined in athymic nude mice. At the low daily dose of 5 μg, EM‐343 administered subcutaneously for 6 months completely blocked the stimulatory effect of endogenous estrogens on the growth of ZR‐75‐1 and MCF‐7 tumors implanted in nude mice. In addition, uterine weight decreased by 60% while ovarian weight increased by 37%. Estrogen receptor (ER) levels measured by [ 3 H]‐labeled estrogen binding were markedly reduced (by 96%, 96% and 92%) in ZR‐75‐1 and MCF‐7 tumors, and in the mouse uterus, respectively. Accompanying the decrease in ER, progesterone receptor levels were reduced by 79%, 87% and 76%, respectively, in the above‐mentioned tissues following EM‐343 treatment. Our data show the pure anti‐estrogenic properties of EM‐343 and its high potency as an inhibitor of growth of human ZR‐75‐1 and MCF‐7 breast tumors in nude mice. Int. J. Cancer 73:735–739, 1997. © 1997 Wiley‐Liss, Inc.